VIDEO: AI-based models may predict visual acuity outcomes after faricimab for DME

ByAnthony DeFino

ByDaniela Ferrara, MD, MSc, PhD

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, discusses AI-based machine learning models to predict the visual acuity treatment response of Vabysmo.

The data were from the phase 3 YOSEMITE and RHINE trials in which patients received Vabysmo (faricimab, Genentech) for the treatment of diabetic macular edema.

“Our models showed some promising performance for the baseline predictions for 1-month or 6-month visual acuity treatment outcomes,” Ferrara said. “We’re super excited about those results because it shows the potential of artificial intelligence to help experts to make more informed decisions.”

Published by:

Sources/Disclosures

Collapse

Source:

Kikuchi Y, et al. Predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema (DME). Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Disclosures: Ferrara reports being an employee of Genentech and having stock options for Roche.

Association for Research in Vision and Ophthalmology

Read more

VIDEO: AI-based models may predict visual acuity outcomes after faricimab for DME

Related Content